- Merck KGaA projects full-year net sales between EUR 20.7 billion and EUR 22.1 billion. The previous forecast was in the same range, and the current estimate is EUR 21.3 billion.
- The company expects adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) to be between EUR 5.8 billion and EUR 6.4 billion. The previous projection was EUR 5.7 billion to EUR 6.3 billion, with an estimate of EUR 6 billion.
- Adjusted earnings per share (EPS) are anticipated to be between EUR 8.20 and EUR 9.30, compared to the previous range of EUR 8.05 to EUR 9.10, with an estimate of EUR 8.64.
- Merck KGaA reported a strong second quarter and has raised its guidance.
- Analyst recommendations: 18 buys, 3 holds, and 0 sells.
A look at Merck KGaA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
According to Smartkarma Smart Scores, Merck KGaA, a global pharmaceutical and chemicals company, holds promising long-term prospects. With solid scores of 3 across Value, Dividend, Resilience, and Momentum, coupled with a Growth score of 4, the company seems well-positioned for growth and stability. Merck KGaA‘s focus on researching drugs in critical areas such as oncology, neurodegenerative, autoimmune, and inflammatory diseases, along with its diverse product portfolio spanning cardiovascular, fertility, and over-the-counter products, signals its robust presence in the market.
In light of its Smart Scores, Merck KGaA displays a balanced outlook, showcasing strength in growth potential, financial stability, and market momentum. As a company deeply rooted in pharmaceutical research and chemical innovation, Merck KGaA‘s strategic positioning and diversified product offerings bode well for its future performance. Investors may find Merck KGaA an attractive investment opportunity given its favorable scores across key factors essential for long-term success.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
